For UK MedTech companies
When buyers see three similar products, yours competes on price by default
Technical parity is the norm in most medtech categories. Without a differentiation strategy built on clinical evidence, implementation support, and outcomes data, margin erosion is structural, not situational.
Two minutes. Solva follows up with specific brand differentiation options.
- Sales teams consistently facing objections about price from NHS procurement or private healthcare providers
- Marketing materials that heavily feature technical specifications but fail to highlight patient outcomes or economic benefits
- Competitors frequently winning tenders based solely on lower pricing, despite offering similar products
- Difficulty securing meetings with key decision-makers who perceive little difference between offerings.
- Increased pressure on sales teams to discount, leading to reduced profitability per deal
- Longer sales cycles and higher customer acquisition costs due to difficulty in demonstrating unique value
- Reduced profit margins and overall profitability due to aggressive price competition
- Stagnant or declining revenue growth as market share is lost to lower-cost competitors
- Perception as a commodity provider rather than an innovative leader in the MedTech space
- Difficulty attracting top talent and strategic partners who seek to align with market innovators
No verified UK data available. However, research consistently highlights the critical role of differentiation in MedTech procurement success and market access. (MedTech Europe, 2020; McKinsey, 2020)
Frequently asked questions
Why does this problem persist?
MedTech markets are often crowded with technically similar products. Differentiation is rarely about the technology - it's about the clinical evidence, the implementation support, the training, and the ongoing relationship. Most companies don't communicate these effectively.
What is the cost of leaving it unaddressed?
No verified UK data available for a precise percentage reduction per deal. However, price-based competition in the MedTech sector is widely acknowledged to exert significant downward pressure on profit margins and can lead to commoditization. (Roland Berger, 2022; AdvaMed, 2020)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.